Neumora Therapeutics (NMRA) Total Current Liabilities (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Total Current Liabilities of $30.1 million for Q1 2026, up 6.1% year-over-year from $28.4 million in Q1 2025, and down 7.2% quarter-over-quarter from $32.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Total Current Liabilities (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 6.1% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $30.1 million (up 6.1% YoY), while the FY2025 annual figure was $32.5 million, up 8.58% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $30.1 million, down from $32.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $32.5 million in Q4 2025, with the low at $21.2 million in Q2 2025.
- The 5-year median for Total Current Liabilities is $27.1 million (2025), against an average of $27.1 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities grew 19.02% in 2024, then declined 18.59% in 2025.
- Neumora Therapeutics' Total Current Liabilities stood at $23.7 million in 2022, then increased by 5.97% to $25.1 million in 2023, then advanced by 19.02% to $29.9 million in 2024, then advanced by 8.58% to $32.5 million in 2025, then decreased by 7.2% to $30.1 million in 2026.
- Business Quant data shows NMRA's Total Current Liabilities at $30.1 million in Q1 2026, $32.5 million in Q4 2025, and $25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 30.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.12 Mn |
| Dec 31, 2025 | 32.45 Mn |
| Sep 30, 2025 | 25.84 Mn |
| Jun 30, 2025 | 21.16 Mn |
| Mar 31, 2025 | 28.38 Mn |
| Dec 31, 2024 | 29.89 Mn |
| Sep 30, 2024 | 31.74 Mn |
| Jun 30, 2024 | 23.13 Mn |
| Mar 31, 2024 | 24.61 Mn |
| Dec 31, 2023 | 25.11 Mn |
| Sep 30, 2023 | 29.12 Mn |
| Dec 31, 2022 | 23.70 Mn |